Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome + 5-FU/LV in Advanced NEC
NCT07014540Phase 4Not yet recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of irinotecan liposome injection in neuroendocrine carcinoma (NEC), sponsored by Beijing Gaobo Hospital. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT07014540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014540.